BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...in Journal for ImmunoTherapy of Cancer (JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...1 NRP1 – Neuropilin 1RAB7A – RAB7A member RAS...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...share. TARGETSCDK4 – Cyclin-dependent kinase 4CDK6 – Cyclin-dependent kinase 6EGFR – Epidermal growth factor receptorKRAS (K-Ras...
...LKB1 ) – Serine/threonine kinase 11 Lauren Martz sotorasib (AMG 510) MRTX849 Mirati Therapeutics Inc. Amgen Inc. KRAS proto-oncogene, GTPase (KRAS) (K-Ras...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...an eye toward “classically undruggable” targets like RAS...
...kinase 4 KEAP1 – Kelch-like ECH-associated protein 1 KRAS (K-Ras...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...polypeptide receptorGLP-1R (GLP1R) – Glucagon-like peptide-1 receptorKRAS (K-Ras) Lauren...
...Martz Carmot Therapeutics Inc. Amgen Inc. KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Glucagon-like...
BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...ErbB1; HER1) – Epidermal growth factor receptorKRAS (K-Ras...
...510) MRTX849 Amgen Inc. Mirati Therapeutics Inc. KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Cancer Non-small...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...under a 2019 deal to run a combination study with the pharma’s SHP-2 inhibitor TNO115.  TARGETSKRAS (K-Ras) SHP-2...
...– Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen Inc. Boehringer Ingelheim GmbH KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Son...
BioCentury | Sep 10, 2020
Regulation

FDA will require data similar to BLA standard for COVID-19 emergency authorization

...some prominent African Americans have made it more difficult to recruit diverse populations. She noted Ras...
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...made it to the clinic, and none have yet reached the market (see “p53 and Ras...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...this year. Lilly drops K-Ras program Eli Lilly and Co. (NYSE:LLY) discontinued development of its K-Ras...
...an effective dose. LY3499446 was in Phase I testing to treat cancer. The most advanced K-Ras...
...year-over-year increase (see “Merck Looks to Lower Barriers” ). Targets CGRP - Calcitonin gene-related peptide K-Ras...
Items per page:
1 - 10 of 1176